Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACA | Q13085 | 2/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.42 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10111315 | 0.87 | ITGB3 (0.54) | ACACAITGB3ITGA2BGPR119CYP2C19 | |
| SCHEMBL17925128 | 0.85 | KCNJ1 (0.49) | ACACAGPR119KCNJ1EGLN2 | |
| SCHEMBL22914827 | 0.83 | EGLN2 (0.52) | GPR119CYP3A4CYP2C19ALDH1A1MAPK1 | |
| SCHEMBL21753280 | 0.83 | ACACA (0.56) | ACACAITGB3ITGA2BKCNJ1CYP3A4 | |
| SCHEMBL289645 | 0.83 | ITGB3 (0.55) | ACACAITGB3ITGA2BGPR119JAK2 | |
| SCHEMBL21753327 | 0.81 | HRH3 (0.55) | ITGB3ITGA2BGPR119CYP3A4CYP2C19 | |
| SCHEMBL21765294 | 0.81 | OPRM1 (0.52) | ACACAITGB3ITGA2BGPR119CYP3A4 | |
| SCHEMBL484627 | 0.80 | CYP11B2 (0.53) | GPR119CYP3A4CYP2C19ALDH1A1MAPK1 | |
| SCHEMBL18357677 | 0.80 | EGLN2 (0.54) | GPR119CYP3A4CYP2C19ALDH1A1MAPK1 | |
| SCHEMBL2301444 | 0.80 | ITGB3 (0.50) | ACACAITGB3ITGA2BACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-20210206766-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-08 | — | — | US | disclosed |
| US-20210206766-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-08 | — | — | US | disclosed |
| WO-2020039029-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039029-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206766-A1 | SPIRO COMPOUNDS AS GLYCOSIDASE INHIBITORS | GLA, BACE1, GAA | ACACA 339/4885ITGB3 3714/4885ITGA2B 3406/4885 |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | GLA, BACE1, GAA | ACACA 339/4885ITGB3 3714/4885ITGA2B 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.